Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors

Wonchan Hwang, Keunok Jung, Youkyoung Jeon, Shik Yun, Tae Woo Kim, Inhak Choi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Tumor microenvironment has emerged as one of the major obstacles against the clinical efficacy of dendritic cell (DC) vaccines. Tumor-derived IL-6 may inhibit the differentiation of hematopoietic progenitor cells into DCs and suppress DC maturation, rendering DCs tolerogenic. We hypothesized that silencing the IL-6 receptor alpha chain (IL-6Rα) would restore the functional competence of DC vaccines in mice with an IL-6-producing TC-1 tumor, and eventually give rise to protective immunity. We found that the IL-6Rα knockdown-DC vaccine significantly enhanced the frequency of tumor-specific CD8+ CTLs-producing effector molecules such as IFN-γ, TNF-α, FasL, perforin, and granzyme B, and generated more CD8+ memory T cells, leading to the substantially prolonged survival of TC-1 tumor-bearing mice.

Original languageEnglish
Pages (from-to)34-44
Number of pages11
JournalVaccine
Volume29
Issue number1
DOIs
Publication statusPublished - 2010 Dec 10

Keywords

  • Dendritic cell vaccine
  • IL-6 receptor
  • Knockdown

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors'. Together they form a unique fingerprint.

  • Cite this